Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study
出版年份 2011 全文链接
标题
Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study
作者
关键词
-
出版物
DIABETES OBESITY & METABOLISM
Volume 13, Issue 11, Pages 1028-1035
出版商
Wiley
发表日期
2011-06-18
DOI
10.1111/j.1463-1326.2011.01460.x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
- (2010) M. A. Nauck et al. DIABETOLOGIA
- Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes
- (2010) Soushou LEE et al. ENDOCRINE JOURNAL
- Pioglitazone: side effect and safety profile
- (2010) Priya Shah et al. Expert Opinion On Drug Safety
- Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus
- (2010) et al. Journal of Diabetes Investigation
- GIP and GLP-1, the two incretin hormones: Similarities and differences
- (2010) Yutaka Seino et al. Journal of Diabetes Investigation
- Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls
- (2010) Daisuke Yabe et al. Journal of Diabetes Investigation
- Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events
- (2009) Bo Ahrén BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus
- (2009) L. BLONDE CLEVELAND CLINIC JOURNAL OF MEDICINE
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2009) Richard E. Pratley et al. CURRENT MEDICAL RESEARCH AND OPINION
- Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
- (2009) R. E. Pratley et al. DIABETES OBESITY & METABOLISM
- Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
- (2009) Richard E Pratley EXPERT OPINION ON PHARMACOTHERAPY
- Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone
- (2009) Priscilla Hollander et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Type 2 diabetes: Where we are today: An overview of disease burden, current treatments, and treatment strategies
- (2009) R. Keith Campbell JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
- Fate of the beta-cell in the pathophysiology of type 2 diabetes
- (2009) R. Keith Campbell JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2008) D. M. Nathan et al. DIABETES CARE
- Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
- (2008) R. A. DeFronzo et al. DIABETES CARE
- Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
- (2008) M. A. Nauck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started